154.72

0.26% 0.40

After Hours: 153.00 -1.72 -1.11%

Protagonist Therapeutics Inc (PTGX)

Overview News Price History Option Chain Financials Why PTGX Down? Discussions Forecast

Protagonist Therapeutics Inc stock is traded at $154.72, with a volume of 483.34K. It is up +0.26% in the last 24 hours and up +13.67% over the past month. Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.

Previous Close:

$154.32

Open:

$154.32

24h Volume:

483.34K

Relative Volume:

0.73

Market Cap:

$10.01B

Revenue:

$74.06M

Net Income/Loss:

$-114.71M

P/E Ratio:

-85.77

EPS:

-1.8039

Net Cash Flow:

$-117.90M

1W Performance:

-2.46%

1M Performance:

+13.67%

6M Performance:

+77.05%

1Y Performance:

+169.17%

1-Day Range:

$149.94

$158.08

1-Week Range:

$148.28

$160.81

52-Week Range:

$54.50

$160.81

Protagonist Therapeutics Inc Stock (PTGX) Company Profile

Name

Protagonist Therapeutics Inc

Sector

Healthcare (1033)

Industry

Biotechnology (582)

Phone

(510) 474-0170

Address

7707 GATEWAY BLVD., SUITE 140, NEWARK, CA

Employee

131

Twitter

Next Earnings Date

2026-08-05

Latest SEC Filings

PTGX's Discussions on Twitter

Compare PTGX vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PTGX Protagonist Therapeutics Inc	154.72	9.75B	74.06M	-114.71M	-117.90M	-1.8039
VRTX Vertex Pharmaceuticals Inc	547.59	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	828.50	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,011.11	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	138.89	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	211.58	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-17-25	Initiated	Barclays	Overweight
Sep-12-25	Initiated	Leerink Partners	Outperform
Jun-17-25	Initiated	Citigroup	Buy
Dec-06-24	Initiated	BMO Capital Markets	Outperform
Dec-06-24	Initiated	Goldman	Neutral
Nov-05-24	Initiated	Wedbush	Outperform
Sep-24-24	Initiated	TD Cowen	Buy
Sep-09-24	Initiated	Truist	Buy
Oct-30-23	Initiated	CapitalOne	Overweight
May-25-23	Resumed	Jefferies	Buy
Aug-25-22	Initiated	JMP Securities	Mkt Outperform
Feb-11-22	Initiated	BTIG Research	Buy
Oct-12-21	Upgrade	JP Morgan	Neutral → Overweight
Oct-11-21	Upgrade	Northland Capital	Market Perform → Outperform
Sep-20-21	Downgrade	JP Morgan	Overweight → Neutral
May-24-21	Initiated	JMP Securities	Mkt Outperform
May-24-21	Initiated	Northland Capital	Outperform
Jan-06-21	Initiated	JP Morgan	Overweight
Dec-16-20	Initiated	Piper Sandler	Overweight
Sep-18-20	Reiterated	H.C. Wainwright	Buy
Jul-15-20	Initiated	Jefferies	Buy
May-18-20	Reiterated	H.C. Wainwright	Buy
Jul-08-19	Initiated	H.C. Wainwright	Buy
May-09-19	Upgrade	Stifel	Hold → Buy
Dec-06-18	Initiated	Nomura	Buy
Jan-29-18	Initiated	Stifel	Buy
Jul-21-17	Initiated	BTIG Research	Buy

View All

Protagonist Therapeutics Inc Stock (PTGX) Latest News

Aug 21, 2026

BlackRock Inc. Makes New Investment in Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Aug 21, 2026

Aug 20, 2026

248,322 Shares in Protagonist Therapeutics, Inc. $PTGX Purchased by Eagle Health Investments LP - MarketBeat

Aug 20, 2026

Great Lakes Advisors LLC Invests $6.97 Million in Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Aug 20, 2026

Aug 18, 2026

Protagonist Therapeutics Reports Granting of Inducement Awards - ACCESS Newswire

Aug 18, 2026

BMO Capital Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $178 - Moomoo

Aug 18, 2026

Protagonist Therapeutics (NASDAQ:PTGX) Hits New 12-Month High on Analyst Upgrade - MarketBeat

Aug 18, 2026

Aug 17, 2026

PTGX Maintained by BMO Capital -- Price Target Raised to $178 - GuruFocus

Aug 17, 2026

Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Expected to Rise, BMO Capital Markets Analyst Says - MarketBeat

Aug 17, 2026

Aug 16, 2026

Johnson & Johnson Invests $300.22 Billion in Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Aug 16, 2026

Aug 15, 2026

Protagonist Therapeutics (NASDAQ:PTGX) Screens as an Affordable Growth Opportunity - ChartMill

Aug 15, 2026

Aug 14, 2026

Protagonist Therapeutics stock hits all-time high at 155.01 USD By Investing.com - Investing.com Australia

Aug 14, 2026

Protagonist Therapeutics stock hits all-time high at 155.01 USD - Investing.com

Aug 14, 2026

Aug 13, 2026

Farallon group (PTGX) discloses 6.43M-share, warrant‑backed stake in Protagonist - Stock Titan

Aug 13, 2026

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Aug 13, 2026

Aug 12, 2026